|
|
|
|
|
|
|
|
|
|
Official Title: "A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer"
A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.....,
Sent from my iPhone
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.